K Pharma,Inc.【JP:4896】Stock Price

K Pharma is a venture company dedicated to developing treatments for neurological diseases. Founded in 2016, the company conducts research, development, manufacturing, and sales of pharmaceuticals and regenerative medicine products based on research outcomes from Keio University School of Medicine. The company focuses particularly on central nervous system disorders, developing treatments for conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, spinal cord injury, and cerebral infarction.

K Pharma operates two business segments: iPS cell drug discovery and regenerative medicine. In iPS drug discovery, the company uses neural cells differentiated from patient-derived iPS cells to conduct efficient compound screening and develop therapeutic drugs for ALS, frontotemporal dementia, Huntington's disease, and other conditions. In regenerative medicine, the company aims to treat spinal cord injury by transplanting neural progenitor cells differentiated from allogeneic iPS cells.

K Pharma's business model leverages intellectual property from universities and research institutions, generating revenue through joint research and development agreements and licensing contracts with pharmaceutical companies. The company receives contract upfront payments, milestone payments, and sales royalties based on these agreements. This approach ensures revenue generation aligned with research and development progress.

K Pharma pursues sustainable corporate value growth by advancing medical innovation to contribute to society, with a particular focus on neurological diseases. The company continues to address unmet medical needs through research and development in drug discovery and regenerative medicine utilizing iPS cells.

K Pharma's growth strategy centers on a hybrid approach combining iPS cell-based drug discovery and regenerative medicine businesses. In drug discovery, the company differentiates neural cells from patient-derived iPS cells and conducts screening with existing pharmaceuticals and compounds. In regenerative medicine, treatment is delivered by directly transplanting cells into damaged areas. This dual approach disperses business risk while enabling technology and knowledge sharing across both operations.

The company leverages industry-academia partnerships with Keio University to execute a "From Basic to Clinical" strategy, translating cutting-edge fundamental research into business applications. It also pursues a "From Rare to Common" strategy, translating rare disease research into treatments for more prevalent conditions. These approaches enhance research and development efficiency and activate business growth.

K Pharma employs an intellectual property-based business model. The company generates revenue through joint research and development agreements and licensing contracts with pharmaceutical companies, based on research outcomes from universities and medical institutions. Particularly in regenerative medicine, the company is strengthening its proprietary development pipeline with the goal of in-house manufacturing and commercialization in the medium to long term.